Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 4, 2013, Pages 468-474

  Benko, Goran ^a   Spajić, Borislav ^b   Krušlin, Božo ^b,c   Tomas, Davor ^b,c  

^a Varazdin General Hospital   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Biochemical recurrence free survival; EpCAM; Prognosis; Prostate cancer

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876724064     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.03.007     Document Type: Article

References (24)

1. Koprowski H., Steplewski Z., Mitchell K., et al. Colorectal carcinoma antigens detected by hybridoma antigens. Somatic Cell Genet 1979, 5:957-971.
2. Trzpis M., McLaughlin P.M., de Leij L.M., et al. Epithelial cell adhesion molecule: More than carcinoma marker and adhesion molecule. Am J Pathol 2007, 171:386-395.
3. Went P., Vasei M., Bubendorf L., et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate, and lung cancers. Br J Cancer 2006, 94:128-135.
4. van der Gun B.T., Melchers L.J., Ruiters M.H., et al. EpCAM in carcinogenesis: The good, the bad, or the ugly. Carcinogenesis 2010, 31:1913-1921.
5. Stoecklein N.H., Siegmund A., Scheunemann P., et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006, 6:165.
6. Went P.T., Lugli A., Meier S., et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35:122-128.
7. Le Naour F., Zoller M. The tumor antigen EpCAM: Tetraspanins and the tight junction protein claudin-7, new partners, new functions. Frontiers Biosci 2008, 13:5847-5865.
8. Gosens M.J., van Kempen L.C., van de Velde C.J., et al. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007, 20:221-232.
9. Went P., Dirnhofer S., Salvisberg T., et al. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 2005, 29:83-88.
10. Munz M., Baeuerle P.A., Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-5629.
11. Poczatek R.B., Myers R.B., Manne U., et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999, 162:1462-1466.
12. Varga M., Obrist P., Schneeberger S., et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004, 10:3131-3136.
13. Xie X., Wang C.Y., Cao Y.X., et al. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 2005, 11:344-347.
14. Shim H.S., Yoon B.S., Cho N.H. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol 2009, 40:693-698.
15. Fong D., Steurer M., Obrist P., et al. Ep-CAM expression in pancreatic and ampullary carcinomas: Frequency and prognostic relevance. J Clin Pathol 2008, 61:31-35.
16. Brunner A., Prelog M., Verdorfer I., et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 2008, 61:307-310.
17. Spizzo G., Went P., Dirnhofer S., et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004, 86:207-213.
18. Baeuerle P.A., Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007, 96:417-423.
19. Spizzo G., Went P., Dirnhofer S., et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006, 103:483-488.
20. Mukherjee S., Richardson A.M., Rodriguez-Canales J., et al. Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol 2009, 175:2277-2287.
21. Zellweger T., Ninck C., Bloch M., et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005, 113:619-628.
22. Sobin L.H., Wittekind C. International Union Against Cancer (UICC): TNM classification of malignant tumours 1997, Wiley Liss, New York, NY. 5th ed.
23. Oberneder R., Weckermann D., Ebner B., et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006, 42:2530-2538.
24. de Bono J.S., Tolcher A.W., Forero A., et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004, 10:7555-7565.